Search
Mevidalen
go.drugbank.com/drugs/DB19034InvestigationalMevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or
Pixatimod
go.drugbank.com/drugs/DB19166InvestigationalPixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide
Synonyms: Pg-545 free acidAzelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigational[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.
Mixtures: N-S-4Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsCarbamide peroxide
go.drugbank.com/drugs/DB11129ApprovedInvestigationalSome adverse effects of carbamide peroxide as a dental bleaching agent include dentin sensitivity and/or gingival irritation led by unstable and reactive H+ free radicals and low pH from prolonged use.
Rheinanthrone
go.drugbank.com/drugs/DB13175ExperimentalRheinanthrone is the active metabolite of senna glycoside DB11365 known for its laxative effect . It is commonly produced by plants of the Rheum species .
Dipotassium phosphate
go.drugbank.com/drugs/DB09414ApprovedInvestigationalDipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.
Mixtures: Isolyte P in Dextrose, ISOLYTE-P PVC 250 ML(SETLI)Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalCell Carcinoma of the Head and Neck- GALAXIES H&N-202). … Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
ABBV-514
go.drugbank.com/drugs/DB17586InvestigationalABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]
Haloprogin
go.drugbank.com/drugs/DB00793ApprovedWithdrawnHaloprogin is no longer available in the United States and has been discontinued.